Related Experiment Video
Updated: Aug 17, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[Antiretroviral treatment. Present and future of the combinations]
1Facultad de Medicina, Universidad de Barcelona, Hospital Clínic, España.
Abstract:
The antiretroviral drugs used in the treatment of infection by the human immunodeficiency virus, type 1, (HIV-1) are reviewed. In Spain zidovudine (AZT), didanosine (ddl) and zacitabine (ddC) are currently available. Recent multicentric trials have shown: 1. That combinations of antiviral drugs are better than monotherapy, 2. That asymptomatic patients may benefit from antiretroviral treatment and 3. That the immunological and virological responses are predictors of the clinical course. It is currently recommended that in patients with a level of less than 350 CD4+ lymphocytes per mm3, treatment should be begun by using a combination of AZT+ddl, or of AZT+ddC. In patients with better immunological status, monotherapy with AZT or ddl has been shown to be useful. Finally the antiretroviral drugs not yet commercially available in Spain are reviewed. By the end of 1996 d4T, 3TC and protease inhibitors will be available and treatment strategies will dramatically change.
Related Concept Videos
Retrovirus Life Cycles
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly

